Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression occurs after 4-6 cycles. The optimal duration of first-line therapy is still unknown and its continuation until disease progression represents the standard. However this strategy is often associated with cumulative toxicity and rapid development of drug resistance. Moreover, only about 40% of AGC pts. are eligible for second-line treatment.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

Soto Parra Hector;
2019-01-01

Abstract

Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression occurs after 4-6 cycles. The optimal duration of first-line therapy is still unknown and its continuation until disease progression represents the standard. However this strategy is often associated with cumulative toxicity and rapid development of drug resistance. Moreover, only about 40% of AGC pts. are eligible for second-line treatment.
Clinical trial; First line; Maintenance; Metastatic gastric cancer; Ramucirumab; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Esophagogastric Junction; Female; Humans; Maintenance Chemotherapy; Male; Paclitaxel; Progression-Free Survival; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome
File in questo prodotto:
File Dimensione Formato  
document-2.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 907.53 kB
Formato Adobe PDF
907.53 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/369792
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact